NCT06557291
- Conditions
- BRAF V600 Mutated-Stage III/IV Melanoma
- Locations
-
- Novartis Pharmaceuticals East Hanover, New Jersey, United States
Clinical trial condition
BRAF V600 Mutated-Stage III/IV Melanoma
Explore clinical trials studying BRAF V600 Mutated-Stage III/IV Melanoma. Study availability and eligibility vary by location and protocol.
1 public trial
0 recruiting studies